PharmGen Science Past Earnings Performance
Past criteria checks 0/6
PharmGen Science's earnings have been declining at an average annual rate of -2.4%, while the Pharmaceuticals industry saw earnings growing at 4.4% annually. Revenues have been growing at an average rate of 15.1% per year. PharmGen Science's return on equity is 1.1%, and it has net margins of 1.6%.
Key information
-2.43%
Earnings growth rate
-3.36%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.32% |
| Revenue growth rate | 15.13% |
| Return on equity | 1.12% |
| Net Margin | 1.63% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Some Investors May Be Willing To Look Past PharmGen Science's (KRX:004720) Soft Earnings
Mar 30
PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 27Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 25Recent updates
Some Investors May Be Willing To Look Past PharmGen Science's (KRX:004720) Soft Earnings
Mar 30PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some Risk
Aug 12PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 27Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?
Mar 21Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%
Jan 19Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?
Dec 21Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 25Revenue & Expenses Breakdown
How PharmGen Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 171,287 | 2,791 | 90,324 | 4,402 |
| 30 Sep 24 | 173,599 | -1,235 | 87,375 | 4,632 |
| 30 Jun 24 | 173,095 | 556 | 86,550 | 4,946 |
| 31 Mar 24 | 171,687 | 6,210 | 84,451 | 5,594 |
| 31 Dec 23 | 166,779 | 6,089 | 81,627 | 5,118 |
| 30 Sep 23 | 159,148 | 4,771 | 78,774 | 4,535 |
| 30 Jun 23 | 154,305 | 7,750 | 74,983 | 3,759 |
| 31 Mar 23 | 147,560 | 13,583 | 71,548 | 2,641 |
| 31 Dec 22 | 150,931 | 70,060 | 68,870 | 2,886 |
| 30 Sep 22 | 144,550 | 84,614 | 66,373 | 2,542 |
| 30 Jun 22 | 135,543 | 87,508 | 62,905 | 2,314 |
| 31 Mar 22 | 126,821 | 68,050 | 64,988 | 2,639 |
| 31 Dec 21 | 109,866 | 32,466 | 61,828 | 2,270 |
| 30 Sep 21 | 103,480 | 25,484 | 62,967 | 2,201 |
| 30 Jun 21 | 99,846 | 24,220 | 61,315 | 2,050 |
| 31 Mar 21 | 97,663 | 32,720 | 53,209 | 1,410 |
| 31 Dec 20 | 96,614 | 9,222 | 52,968 | 1,115 |
| 30 Sep 20 | 94,287 | 2,202 | 47,947 | 909 |
| 30 Jun 20 | 93,162 | -432 | 47,383 | 813 |
| 31 Mar 20 | 94,875 | -1,355 | 48,452 | 824 |
| 31 Dec 19 | 95,138 | 302 | 47,055 | 886 |
| 30 Sep 19 | 94,214 | 2,323 | 45,505 | 944 |
| 30 Jun 19 | 94,198 | 2,712 | 44,286 | 1,041 |
| 31 Mar 19 | 90,923 | 4,076 | 41,313 | 1,227 |
| 31 Dec 18 | 89,102 | 4,468 | 39,552 | 1,240 |
| 30 Sep 18 | 87,803 | 3,989 | 38,215 | 1,333 |
| 30 Jun 18 | 85,413 | 5,267 | 36,119 | 1,244 |
| 31 Mar 18 | 82,127 | 4,510 | 35,245 | 1,012 |
| 31 Dec 17 | 79,894 | 4,320 | 34,140 | 986 |
| 30 Sep 17 | 75,417 | 4,869 | 33,787 | 908 |
| 30 Jun 17 | 73,487 | 3,811 | 33,844 | 884 |
| 31 Mar 17 | 71,994 | 2,638 | 34,505 | 799 |
| 31 Dec 16 | 71,546 | 3,452 | 34,407 | 694 |
| 30 Sep 16 | 71,531 | 2,087 | 33,212 | 618 |
| 30 Jun 16 | 67,757 | 369 | 31,564 | 544 |
| 31 Mar 16 | 64,735 | 2,202 | 28,893 | 544 |
| 31 Dec 15 | 60,405 | 2,067 | 26,885 | 529 |
| 30 Sep 15 | 54,461 | -459 | 26,358 | 478 |
| 30 Jun 15 | 51,294 | -202 | 26,631 | 470 |
| 31 Mar 15 | 47,986 | -2,604 | 26,851 | 436 |
| 31 Dec 14 | 44,203 | -4,584 | 26,689 | 437 |
| 30 Sep 14 | 42,039 | -4,327 | 25,675 | 423 |
| 30 Jun 14 | 40,326 | -4,316 | 25,394 | 311 |
Quality Earnings: A004720 has a large one-off loss of ₩3.1B impacting its last 12 months of financial results to 31st December, 2024.
Growing Profit Margin: A004720's current net profit margins (1.6%) are lower than last year (3.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A004720's earnings have declined by 2.4% per year over the past 5 years.
Accelerating Growth: A004720's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A004720 had negative earnings growth (-54.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (0.06%).
Return on Equity
High ROE: A004720's Return on Equity (1.1%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/17 02:19 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmGen Science, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.